CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

RFA: Bosulif for Chronic Myeloid Leukemia – Details

Project Number PA0002-000
Brand Name Bosulif (RFA)
Generic Name Bosutinib
Tumour Type Leukemia
Indication Chronic Myeloid Leukemia
Review Status Complete
Pre Noc Submission
NOC Date
Manufacturer Pfizer Canada Inc.
Sponsor pCODR Provincial Advisory Group
Submission Date April 8, 2019
Submission Type Request for Advice
Prioritization Requested
Stakeholder Input Deadline ‡ April 23, 2019
Check-point meeting (target date)
pERC Meeting July 18, 2019
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued August 2, 2019
Therapeutic Area Chronic Myeloid Leukemia

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.